

NUFFIELD DEPARTMENT OF PRIMARY CARE HEALTH SCIENCES Medical Sciences Division

Distribution of Type-2 Biomarkers of Asthma in a Healthy Adult Population – **A Cross-Sectional Study**

Cameron Doyle¹, Haopeng Xu^{2,3,4}, Denise Fleming-Brown², Beverly Langford², Ian Pavord², Nayia Petousi², Helen Ashdown^{5,6}

¹Medical Sciences Division, University of Oxford, United Kingdom, ²Nuffield Department of Medicine, University of Oxford, United Kingdom, ³ Department of Physiology, Anatomy and Genetics, University of Oxford, ⁴ CAMS-Oxford Institute, University of Oxford ⁵ Nuffield Department of Primary Care Health Sciences, University of Oxford ⁶ NIHR HealthTech Research Centre in Community Healthcare



cameron.doyle@stcatz.ox.ac.uk

Background

Asthma is characterised by distinct phenotypes, with 50-70% of severe cases involving type-2 (eosinophilic) inflammation, which can be treated with oral or inhaled steroids and biological treatments. Type-2 inflammatory biomarkers can be easily measured in the community using fractional exhaled nitric oxide (FeNO) and blood eosinophil count (BEC). We hypothesise that some individuals may have type-2 inflammation present without symptoms, which may represent a target for earlier identification and treatment.

Results

Figure 1:

Data from 87 participants is reported:

Mean age = **30.3 years** (± 9.1) **28 (32%)** of participants were **male** 11 (13%) of participants were current or ex-smokers

Median FeNO = 18 ppb (range: 12 - 32) Median BEC = $0.1 \times 10^{9}/L$ (range: 0.1 - 0.2)

Objective:

To identify the distribution of type-2 biomarkers (FeNO and BEC) in healthy young adults without asthma

Methods

- **Aged 18-50 without respiratory disease** Inclusion:
- *Exclusion*: Respiratory disease and/or immunosuppressive medication use.

Participants underwent FeNO measurement using the NIOX VERO® (see below) and eosinophil measurement using the HemoCue® WBC DIFF **system** from a fingerprick blood sample.






Figure 2:

Males had a higher median FeNO than females (31.5 vs. 16; p < 0.001), but there was no significant difference between the sexes for BEC.

FeNO (ppb) in females and males



Following FeNO testing and point-of-care BEC measurement, participants were stratified according to the following biomarker categories:

Biomarker stratification category	FeNO and BEC cut-offs
Low	FeNO < 25 ppb
	or
	BEC ≤ 0.15 x 10 ⁹ /L
Moderate	FeNO 25 – 49 ppb
	or
	BEC 0.15 – 0.29 x 10 ⁹ /L






Figure 3:

Higher BEC ($\geq 0.3 \times 10^9/L$) was associated with increased atopy – 92% of those with BEC $\ge 0.3 \times 10^9$ /L experienced atopic symptoms compared to 34.7% of those with BEC < $0.3 \times 10^{9}/L (p = 0.002).$





Our study found that 18.4% of healthy young adults have ≥ 1 raised

biomarker indicative of eosinophilic airways disease. This was associated

with atopy, suggesting pre-symptomatic of subclinical airways disease. Long-term evaluation of these individuals is required to explore their future airways

disease risk and whether pre-symptomatic treatment to reduce inflammation could alter their disease trajectory.

This research project received ethics approval from a subcommittee of the University of Oxford Central University Research Ethics Committee (reference) R87777/RE001). HA receives funding from the NIHR HealthTech Research Centre in Community Healthcare at Oxford Health NHS Foundation Trust. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.